key: cord-1027862-hu3e5nzw
authors: Bain, William G.; Peñaloza, Hernán F.; Ladinsky, Mark S.; van der Geest, Rick; Sullivan, Mara; Ross, Mark; Kitsios, Georgios D.; Methe, Barbara; McVerry, Bryan J.; Morris, Alison; Watson, Alan M.; Watkins, Simon C.; St Croix, Claudette M.; Stolz, Donna B.; Bjorkman, Pamela J.; Lee, Janet S.
title: Lower respiratory tract myeloid cells harbor SARS-CoV-2 and display an inflammatory phenotype
date: 2020-11-18
journal: Chest
DOI: 10.1016/j.chest.2020.10.083
sha: 805a85dd691863b99cbafcbfd39a7fd96248e199
doc_id: 1027862
cord_uid: hu3e5nzw

nan

Allergy and Infectious Diseases (NIAID) Grant 2 P50 AI150464 (P.J. B.) , and that EM was performed using a TF-30 electron microscope maintained by the California Institute of Technology Kavli Nanoscience Institute.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, Department of Veterans Affairs, or any other sponsoring agency. 1 Although the clinical implications are unclear, others have suggested that infiltrating myeloid cells may contribute to morbidity and mortality during SARS-CoV-2 infection. [1] [2] [3] However, few reports have characterized myeloid cells from the lower respiratory tract, which appears to be the primary site of viral-induced pathology, during severe SARS-CoV-2 pneumonia.

Endotracheal aspirate (ETA) samples were prospectively collected from seven patients requiring mechanical ventilation for severe pneumonia due to SARS-CoV-2 infection as documented by RT-PCR during April-June 2020. All patients were enrolled in a University of Pittsburgh lung injury registry and biospecimen repository (IRB# PRO10110387). ETA were fixed in paraformaldehyde overnight then processed for subsequent imaging. Briefly, ETA samples were washed twice then pelleted at 600 g. Samples for electron microscopy were re-suspended in glutaraldehyde, re-pelleted at 600 g, and processed as described in a prior report. 4 Samples for light microscopy and immunofluorescence were re-suspended in phosphate-buffered saline then prepared as cytospins by spinning at 300 RPM onto a Superfrost plus microscope slide (Fisher Scientific).

Manual cell counts of ETA samples were performed after Diff-Quick (Siemens) staining and representative images were obtained utilizing an Olympus Provis I microscope. For immunofluorescence, cytospin slides were placed in 70% (volume/volume) ethyl alcohol followed by 90% (volume/volume) ethyl alcohol for 10 minutes each, then allowed to air dry. Antibodies used include SARS-CoV-2 nucleocapsid protein (Novus Biologicals NB100-56576), CD14 (BD Biosciences #347490), CD16 (Invitrogen MA1-84008), CD142 (Tissue Factor; BD 550252), and IL-6 (Novus NBP2-44953). Subsequent staining was performed, and slides were imaged using a Nikon A1 confocal scanning fluorescence microscope. Pre-embed immune-electron microscopy was performed after cytospin preparation with colloidal gold-conjugated secondary antibodies (Jackson ImmunoResearch; 18 nm -CD14, 6 nm -SARS_CoV-2 Nucleocapsid) using a JEOL JEM 1400 transmission electron microscope at 80 KV with image capture via an Advanced Microscopy Techniques 2k digital camera. RNAscope was J o u r n a l P r e -p r o o f performed per manufacturer instructions. Quantitative imaging analysis was performed using object-based area overlap analysis via Nikon Elements software. Statistical comparisons of co-expression of CD14, CD16, IL-6, and tissue factor in cells with or without SARS-CoV-2 Nucleocapsid protein were performed using nonparametric testing in Prism GraphPad V7.05.

The median age of the seven patients was 58 (range 56-77) and five (71.4%) were male. The median duration of reported symptoms prior to initiation of mechanical ventilation was 7 days (range 3-11). Samples were collected within a median of 5 days (range 1-14) after initiation of mechanical ventilation. Notably, three patients required extra-corporeal membrane oxygenation and two patients were deceased by 60 days of followup from intensive care unit admission. There were no patients with known immune deficits in this cohort as defined by history of immuno-suppressive therapy, including chemotherapy or chronic systemic steroids, or known immune deficiency. Endotracheal aspirates were primarily composed of mononuclear and polymorphonuclear leukocytes ( Figure 1A , range 70.6-97.5% of nucleated cells). Electron tomography of endotracheal aspirates revealed intra-cellular localization of presumptive SARS-CoV-2 virions in mononuclear leukocytes (representative image, Figure 1B ) and polymorphonuclear leukocytes (representative image, Figure   1C ). The identification of SARS-CoV-2 virions by electron tomography was consistent with immune-electron microscopy using an antibody against the Nucleocapsid protein of SARS-CoV-2 that confirmed the presence of virus in CD14 + cells in the lower airways (representative image, Figure 1D ). Quantitative imaging of ETA cells revealed SARS-CoV-2 Nucleocapsid protein expression (Figure 2A ; n=6; Patient 7 did not have sufficient ETA available for imaging), many of which were also positive for CD14, CD16, IL-6, and tissue factor immunostaining (representative image, Figure 2B ). Myeloid cells that expressed SARS-CoV-2 Nucleocapsid protein were more likely to express the inflammatory markers CD14 and CD16 ( Figure 2C Figure 2D ; p<0.01) and tissue factor ( Figure 2D ; p<0.05) compared to cells without co-localization of viral protein within each sample. Finally, we noted that endotracheal aspirate myeloid cells showed IL6, F3 and CD14 transcripts (representative image of polymorphonuclear leukocyte, Figure 2E ). Therefore, it remains to be determined whether productive replication of SARS-CoV2 can occur in these cells.

A limitation of our study is that endotracheal aspirates may not fully reflect the distal airspaces and we suggest that these findings should be validated in bronchoalveolar lavage samples. Further work in preclinical models of 

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Immunology of COVID-19: Current State of the Science

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Mechanisms of virus dissemination in bone marrow of HIV-1-infected humanized BLT mice

Histopathological and immunohistochemical findings of 20 autopsy cases with 2009 H1N1 virus infection

Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

SARS-coronavirus replication in human peripheral monocytes/macrophages

Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis

Quantitative immunofluorescence with median percentage (n=3 slides per patient) of total ETA cells that expressed SARS-CoV-2 Nucleocapsid protein (n=6 patients, Patient 7 did not have sufficient endotracheal aspirate for immunofluorescence staining)

Representative montage from a single polymorphonuclear cell illustrating co-localization by immunofluorescence. Panels from left to right show: a) merge, b) CD14 (green), c) IL-6 (red), d) SARS-CoV-2 Nucleocapsid protein (white), and e) Imaris (Bitplane) surface rendered image of the overlapping areas of labeling

Comparison of endotracheal aspirate cells that co-expressed CD14 (14) or CD16 (16) with (N+) or without (N-) SARS-CoV-2 Nucleocapsid protein in each sample (n=5 patients; Patient 2 was removed due to low number of cells with Nucleocapsid protein)

Comparison of endotracheal aspirate cells that co-expressed IL-6 (IL-6+) or tissue factor (TF+) with (N+) or without (N-) SARS-CoV-2 Nucleocapsid protein in each sample (n=5 patients; Patient 2 was removed due to low number of cells with Nucleocapsid protein). Statistical comparison by Mann-Whitney test

IL6 (white), and tissue factor or F3 (red) transcript as well as DAPI nuclear staining (blue) in ETA myeloid cell

Quantitative immunofluorescence with median percentage (n=3 slides per patient) of total ETA cells that expressed SARS-CoV-2 Nucleocapsid protein (n=6 patients, Patient 7 did not have sufficient endotracheal aspirate for immunofluorescence staining)

Representative montage from a single polymorphonuclear cell illustrating co-localization by immunofluorescence. Panels from left to right show: a) merge, b) CD14 (green), c) IL-6 (red), d) SARS-CoV-2 Nucleocapsid protein (white), and e) Imaris (Bitplane) surface rendered image of the overlapping areas of labeling

Comparison of endotracheal aspirate cells that co-expressed CD14 (14) or CD16 (16) with (N+) or without (N-) SARS-CoV-2 Nucleocapsid protein in each sample (n=5 patients; Patient 2 was removed due to low number of cells with Nucleocapsid protein)

Comparison of endotracheal aspirate cells that co-expressed IL-6 (IL-6+) or tissue factor (TF+) with (N+) or without (N-) SARS-CoV-2 Nucleocapsid protein in each sample (n=5 patients; Patient 2 was removed due to low number of cells with Nucleocapsid protein). Statistical comparison by Mann-Whitney test